NGM
$17.44
Ngm Biopharmaceuticals
$.10
.58%
NGM
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.39)
Revenue:  $18.33 Mil
Tuesday
Nov 10
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NGM reports earnings?
Beat
Meet
Miss

Where is NGM's stock price going from here?
Up
Flat
Down
Stock chart of NGM
Analysts
Summary of analysts' recommendations for NGM
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California.